8/7/2013 6:31:31 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
DUBLIN, Aug. 6, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter ended June 30, 2013 and updated 2013 financial guidance.
"During the second quarter, we continued our track record of delivering strong top and bottom line growth fueled by increasing sales of Xyrem® and Erwinaze®," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by